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MARIBAVIR IS BIOEQUIVALENT IN FED AND FASTED HEALTHY
SUBJECTS
Goldwater, R.1, Johnson, J.2, Schumacher, M.2, Villano, S.2 1PAREXEL
International, Baltimore, MD; 2ViroPharma Incorporated, Exton,
PA
Background: Maribavir (MBV) is an orally bioavailable antiviral
drug with a novel mechanism of action against human cytomegalo-
virus (CMV) and a favorable tolerability profile. MBV is rapidly
and well absorbed following oral administration with peak plasma
concentrations generally achieved between 1.0 and 3.0 h post dose.
In single-dose studies in healthy (50–1600 mg) and HIV-infected
(100–1600 mg) subjects, the pharmacokinetics (PK) of MBV are
approximately linear. This study was designed to determine the
effect of co-administration of a moderately high-fat meal on the
pharmacokinetics of MBV.
Methods: This study was an open-label, randomized, crossover
design performed at one investigational site. The study population
included 15 men and 15 women and had a mean age of 29 years
(range, 21–40 years). Eighteen subjects (60%) were black and 12
(40%) were white. Subjects received a single 400-mg dose of MBV
administered as 2  200-mg tablets either after an overnight fast
or within 5 minutes after completion of a standard, moderately
high-fat breakfast. Treatments were separated by a 7- to 14-day
washout interval. A full pharmacokinetic (PK) evaluation was per-
formed over the 24 hours following each treatment. Standard safety
monitoring was performed.
Results: Oral MBV 400 mg was generally well tolerated when
administered under either fasting or fed conditions. The most
frequently reported treatment-emergent event was taste disturbance
which occurred in 14/29 (48%) subjects. Mean (SD) PK parameters
for MBV under fasting and fed conditions are shown below with
results from ANOVA.
Ratio ofFasting
With
FoodGeometric
Means (90%CI)Tmax (h) 1.57 (0.68) 2.47 (0.87) Different*
Cmax (mcg/mL) 16.7 (5.4) 11.7 (2.4) 0.722 (0.656, 0.793)
AUC(0-t) (mcg*h/mL) 101 (36.4) 86.3 (29.1) 0.860 (0.802, 0.922)
AUC(0-inf) (mcg*h/mL) 106 (42.0) 91.5 (33.9) 0.864 (0.804, 0.929)*For Tmax, the p-value for testing for treatment effects was\0.0001 for
MBV administered with food versus fasting conditions.
Time toMBVCmax was delayed by administration after a high fat
meal (Tmax 2.5 hours vs. 1.6 hours under fasting conditions). Al-
though there is a decrease in AUC when MBV is administered
with food, AUC values are considered equivalent as the 90% CIs
are within the 0.80 to 1.25 range. Based on the ratio of geometric
means of the two treatments, Cmax is 28% lower for MBV adminis-
tered with food compared with fasting conditions (p\0.0001).
Conclusions: A moderately high-fat meal was shown to have
a modest effect on Cmax of MBV and to delay Tmax by about 1
hour but does not substantially alter the total exposure toMBV.These
findings suggest that MBV can be taken without regard to food.295
SAFETY PROFILE OF PHARMACOKINETICALLY TARGETED INTRAVENOUS
BUSULFAN COMBINED WITH FLUDARABINE (BUFLU) AS CONDITIONING
PRIOR TO ALLOGENEIC PERIPHERAL BLOOD HEMATOPOIETIC CELL
TRANSPLANT
Perkins, J.1, Alsina,M.1, Ayala, E.1, Fancher, K.2, Fernandez, H.1, Khar-
fan-Dabaja, M.1, Ochoa-Bayona, L.1, Perez, L.1, Raychaudhuri, J.1,
Sullivan, D.1, Tate, C.2, Field, T.1 1Moffitt Cancer Center, Tampa,
FL; 2Moffitt Cancer Center, Tampa, FL
We report here our experience with 105 pts with hematologic ma-
lignancies treated with busulfan (Bu) and fludarabine (Flu) as condi-
tioning prior to allogeneic hematopoietic cell transplant. Bu was
dosed at 100–145mg/m2/day on days 1 and 2 with pharmacokinetic
targeting for days 3 and 4; the dose of Flu was 40mg/m2/day for 4days. The median age was 47.6 years (range 22–67 years). Forty-one
pts received grafts from matched siblings, 48 from matched URD,
and 16 from URD mismatched at 1 antigen/allele. Disease status
was categorized as low risk (no evidence of disease) in 54 pts, interme-
diate risk (\20% BM blasts or chemosensitive lymphoma) in 36 pts,
and high risk ($20%BMor any circulating blasts or chemorefractory
lymphoma) in 15 pts. Bu doses were targeted to area under the con-
centration time curve (AUC) value of 3500–5850 uM*min, depending
on diagnosis and disease status. Median actual AUC after a dose of
130mg/m2 was 4692 uM*min (range 2633–8219 uM*min) and doses
3 and 4 were adjusted in 69 pts (66%) to achieve the overall target
AUC. Median total Bu doses to achieve target AUC of 5300/day
was 520mg/m2 (range 332–1040mg/m2). Pts received tacrolimus
and methotrexate or mycophenolate as GVHD prophylaxis. Grade
2–4 and 3–4 acute GVHDoccurred in 76 (72%) and 24 (23%) pts, re-
spectively. Moderate to severe chronic GVHD occurred in 54 of 84
(64%) evaluable pts. All pts received anti-seizure prophylaxis with ei-
ther phenytoin or lorazepam; no seizures occurred within the first 72
hours after the completion of Bu. Moderate to severe toxicities ob-
served that were at least possibly related to Bu included grade 3 or
4 elevations in hepatic transaminases in 12 pts (11%), hepatic
VOD/SOS in 4 pts (4%), and interstitial pneumonitis in 2 pts (2%).
100 day and 1 year non-relapse mortality were 7% and 20% respec-
tively. Overall and event-free suvival at 2 years for the low risk versus
intermediate or high risk groups were 62% and 59% vs 39% and 33%
(p5 0.03 for both comparisons). We conclude that using pharmaco-
kinetically targeted busulfan in combination with fludarabine offers an
active and well-tolerated approach to allogeneic transplantation. Due
to the large range in dosing required to achieve a desired AUC, phar-
macokinetic targeting is recommended. While others are evaluating
the benefit of targeting Bu dosing in a more formal manner, we are
exploring the maximumally tolerated systemic exposure to Bu based
on pharmcokinetic targeting in a prospective clinical trial.296
PLATELET ENGRAFTMENT IN AML PATIENTS RECEIVING MATCHED RE-
LATED DONOR (MRD) ALLOGENEIC BONE MARROW TRANSPLANT (AL-
LOBMT) CORRELATES WITH MAJOR HISTOCOMPATIBILITY COMPLEX
CLASS I-RELATED MOLECULE A (MICA) GENE POLYMORPHISMS
Sobecks, R.M.1, Askar, M.2, Zhang, A.2, Thomas, D.2, Kawczak, P.2,
Pidwell, D.2, Rybicki, L.3, Jasek, M.1, Kalaycio, M.1, Andresen, S.1,
Pohlman, B.1, Dean, R.1, Copelan, E.1, Maciejewski, J.1, Bolwell, B.1
1Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH; 2Cleveland
Clinic, Cleveland, OH; 3Cleveland Clinic, Cleveland, OH
Recipient immune effector cells such as CD81, TCRab1 and
TCRgd1 T cells as well as NK cells have been implicated in resis-
tance to platelet engraftment (PE) after alloBMT. MICA is a ligand
recognized by the activating receptor NKG2D that is expressed on
the surface of NK, NKT, CD81 and TCRgd1 T cells. Allelic vari-
ants of MICA due to a single amino acid substitution at position 129
in the alpha2 domain have been reported to result in large differences
in NKG2D binding. MICA alleles with a methionine (129M) or va-
line (129V) have been classified as having strong or weak binding af-
finity for NKG2D, respectively. These variable affinities have been
suggested to affect thresholds of NK cell triggering and T cell mod-
ulation. It has also been reported that homozygosity of 129M alleles
was associated with early onset ankylosing spondylitis. However, the
effect such polymorphisms have on outcomes afterMRDalloBMT is
unknown. 69AMLptswho hadMRDalloBMTwith busulfan/cyclo-
phosphamide conditioning were genotyped to determineMICA 129
dimorphism. MICA typing was performed retrospectively on DNA
samples from donors and recipients by rSSOP. Pts were categorized
as 129VV (weak, n5 32), 129MV (mixed, n5 33) or 129MM(strong,
n 5 4) dimorphisms. Post-transplant outcomes were compared be-
tween pts with weak vs. mixed/strong binding affinities. Outcomes
were estimated using the Kaplan-Meier method and compared be-
tween groups with the log-rank test. Pts in the weak binding affinity
grouphadmore rapidPE to.20K/mLthan those in themixed/strong
group [median 17 vs. 25 days, respectively, p 5 0.006]. The weak
binding group also tended to have inferior relapse-free survival
(p 5 0.09). There were no differences between the weak and
mixed/strong binding affinity groups with regards to pre-BMT pt
characteristics, CD341/TNC doses, neutrophil engraftment, acute
108 Poster Session-IIor chronic GVHD, CMV/other infections, graft rejection or overall
survival.We conclude that assessment ofMICAgene polymorphisms
in MRD alloBMT pts may have important implications for predict-
ing post-transplant outcomes. Thosewith aMICAdimorphism indi-
cating weak binding affinity for theNKG2D activating receptor may
have less alloreactive recipient immune effector cells that allow for
more rapid PE. This group may also be less likely to generate graft-
vs.-leukemia responses. Further investigation of this observation
with larger study populations is warranted.297
LONG–TERM SURVIVAL OF ALLOGENEIC TRANSPLANTATION(ALLO SCT)
IN SELECTED PATIENTS WITH MULTIPLE MYELOMA (MM): DISEASE
FREE SURVIVAL AT TWO YEARS MAY INDICATE LONG TERM SURVIVAL
Raychaudhuri, J., Perkins, J., Alsina, M., Ochoa-Bayona, J.L.,
Fernandez, H., Sullivan, D., Dalton, W., Kharfan-Dabaja, M.,
Field, T., Ayala, E., Perez, L., Harris, J.C., Janssen, W., Tate, C.,
Anasetti, C. H. Lee Moffitt Cancer Center and Research Institute, Tampa,
FL
Introduction: Allo SCT offers long term control and in some
cases cure in patients with MM. In this study we reviewed our expe-
rience at H. Lee Moffitt Cancer Center, of Allo SCT for MM and
examined indicators of long term survival.
Patient andMethods: A retrospective analysis was performed on
patients withMMwho underwent allo SCT between 1996 to 2008 at
our institution. Kaplan-Meier estimates were used to determine
overall and progression free survival.
Results:Thirty-one patients (18males and 13 females) underwent
AlloSCT for MM between 1996 and 2008. The median age was 45
years (range 29–63). The majority (64%) were Durie-Salmon stage
III at diagnosis. Most patients (74%) received at least 2 lines of prior
treatment and 16 received prior autologous transplant including 4
who received 2 autotransplants(2 out 4 were tandem).Disease status
prior to Allo SCT included 4 CR, 3 VGPR, 11 PR and 5\PR in the
data available in 23 patients. Ten patients had genetic high risk fea-
tures. 18 patients received matched related donors grafts (one synge-
neic) and 9 received matched unrelated donor grafts and 2 received
unrelated donors grafts mismatched at one allele. Eight patients
got TBI containing regimens and 2 patients Bu-Cy prior to 2002.
Subsequently either busulfan-fludarabine (5 patients) or melpha-
lan-fludarabine (12 patients) were used as conditioning regimens.
GVHD prophylaxis was tacrolimus plus methotrexate or mycophe-
nolate. Incidence of acute GVHD requiring treatment was 54.8%
and chronic GVHD was 42.8%. Non-relapse mortality at 100 days
was 22.5%. Post allograft the response levels were 12 CR, 3
VGPR, 2 PR, 7 \PR. Out of the 12 patients who achieved CR
post allograft 2 were VGPR, 2 were PR and 1 was progressive disease
prior to allogeneic transplant. Three patients were in continuingCR.
Overall survival at 1 year, 2 year, 5 year was 77%, 68%, and 54% re-
spectively. Event free survival at 1 year, 2 year, 5 year was 57%, 46%
and 46% respectively.
Conclusions:AlloSCT inMMallow for long term remissions and
survival in over 50% of patients treated with this approach. Relapses
are rare in those patients who remain in remission after 2 years. A
majority (4 out of 5 patients) of the long term survivors (.100
months) did get TBI containing regimens in this analysis. However
the melphalan-fludarabine patients look promising, but require lon-
ger follow up. A multivariate analysis of the prognostic factors is
ongoing.298
FOLLOW-UP OUTCOMES OF RELATED AND UNRELATED DONOR
HEMATOPOIETIC CELL TRANSPLANTATION FOR BETA-THALASSEMIA
PATIENTS
Vanichsetakul, P. Bangkok Hospital Medical Center, Bangkok, Thailand
Beta-thalassemia diseases are very prevalent in Thailand. Alloge-
neic hematopoietic stem cell transplantation (HCT) is the only ac-
ceptable therapeutic method to cure them. In this case-series study
there were 61 patients, one of which underwent HCTs twice
(BMT, then PBSCT) from same sibling donor. So, total 62 HCTs
were performed in single medical institute in Bangkok from July1999 to June 2008, including 42 BMTs, 9 PBSCTs, and 11 CBTs.
The detailed diagnoses were 54 cases of beta-thalassemia/hemoglo-
bin E, 6 of homozygous beta-thalassemia, and 1 of EFBart’s disease.
Patients’ age at transplant varied from18months to 14 years 8months
withmedian of 6 years. According to Pesaro classification, there were
25 class I, 27 class II, and 9 class III patients. Considering by donor
types, there were 34 patients in HLA-matched sibling, 2 in mis-
matched related cord blood, 22 in matched unrelated, 2 in one-anti-
gen mismatched unrelated cord blood, and 1 in mismatched
unrelated donor HCT groups. The mainstay of conditioning regi-
men contained busulfan (oral or intravenous), cyclophosphamide,
and anti-thymocyte globulin. Fludarabine was utilized in addtion
for most of unrelated donor HCT. Cyclosporine and methotrexate
were used as GVHDprophylaxis in matched related group, while ta-
crolimus was used instead of cyclosporine in unrelated group. 50 pa-
tients achieved donor engraftment and were considered as cured. 5
patients were alive but still with disease, and 6 patients died. Among
11 engrafted patients who previously developed acuteGVHD, only 1
matched-sibling PBSCT patient remained having chronic extensive
GVHD.Median follow-up time for surviving 55 patients was 3 years
3 months (range 4 months to 9 years 3months). To date the overall
(OS) and disease-free survival (DFS) for all patients were 90.2%
and 82%, respectively. Categorized by risk class, the OS and DFS
for class I patients were 92% and 88%, class II were 100% and
92.6%, and class III were 55.6% and 33.3%, respectively. Classified
by degree of HLA match, the OS and DFS for complete-matched
patients (n 5 56) were 92.9% and 87.5%, and mismatched patients
(n5 5) were 60% and 20%, respectively. In group of HLA-matched
HCT, the OS andDFS for patients receiving related donor stem cell
(n 5 34) were 97.1% and 94.1%, and ones getting unrelated donor
stem cell (n 5 22) were 90.9% and 81.8%, respectively. The fol-
low-up outcomes of these thalassemia patients have been convincing
as favorable and comparable to other studies.299
INTENSIVE PREPARATIVE REGIMEN EMPLOYING BUSULFAN, CYCLO-
PHOSPHAMIDE, AND TOTAL BODY IRRADIATION FOLLOWED BY ALLO-
GENEIC STEM CELL TRANSPLANTATION FOR MYELOID MALIGNANCIES
Yano, S.1, Usui, N.1, Dobashi, N.1, Yahagi, Y.1, Takei, Y.1,
Sugiyama, K.1, Ogasawara, Y.1, Takahara, S.1, Yamaguchi, Y.1,
Saito, T.1, Okawa, Y.1, Minami, J.1, Yokoyama, H.1, Kobayashi, T.1,
Otsubo, H.2, Hoshi, Y.2, Asai, O.1, Aiba, K.1 1Jikei University School of
Medicine, Tokyo, Japan; 2Jikei University School of Medicine, Tokyo,
Japan
Purpose: Intensive conditioning regimens given prior to alloge-
neic stem cell transplantation (allo-SCT) is able to bring durable re-
missions but increase treatment-related mortality (TRM). We
retrospectively evaluated the efficacy and safety of a conditioning
regimen consisting of busulfan (BU), cyclophosphamide (CY), and
total body irradiation (TBI) for patients with myeloid malignancies.
Patients and methods: FromNovember 1990 to February 2008,
85 patients (AML 38, CML 29,MDS 18) received BU (8mg/kg), CY
(120 mg/kg), and TBI (10 Gy) followed by related (n5 46) or unre-
lated (n5 39) allo-SCT. Patients with AML in 1st or 2nd remission,
CML in chronic phase, and MDS (less than 5%marrow blasts) were
defined as having a standard-risk group (n 5 55), and patients with
advanced diseases were defined as having a high-risk group (n5 30).
Results: Median follow-up was 8.4 (0.3–18.9) years, and median
age of patients was 35 (17–55) years old. The 8-year actuarial re-
lapse-free survival rates for all patients, standard-risk patients and
high-risk patients were 54%, 62% and 36%, respectively. Probabil-
ity of relapse rates for all patients, standard-risk patients and
high-risk patients were 22%, 14% and 42%, respectively. Hepatic
veno-occlusive disease was occurred in 3 patients (4%), and one of
them died of the disease. The cumulative incidence of TRM of all
patients was 26% (standard-risk 25%, high-risk 27%). Because
cytomegalovirus (CMV) disease was amajor cause of mortality follow-
ing allo-SCT before 1997, the incidence of TRM decreased to 13%
(standard-risk 10%, high-risk 16%) in the era of cytomegalovirus pre-
emptive therapy and no patient has died of CMV disease since 1998.
Conclusion:These results show that the combination of BU, CY,
andTBI seems to be one of effective intensive conditioning regimens
for allo-SCT in myeloid leukemia with a low TRM in the era of cy-
tomegalovirus preemptive therapy.
